日本高潮视频在线观看-亚洲中文字幕永不卡-精品亚洲一区二区三区-伦理片夜夜躁狠狠躁日日躁-日本最新免费不卡二区-国产精品口爆一区二区三区-av一区二区三区高清-大鸡巴疯狂抽插小穴视频-日韩中文国产在线观看免费视频

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. FCGRT (Rozanolixizumab Biosimilar) Recombinant Monoclonal Antibody

FCGRT (Rozanolixizumab Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA008545MB4HU
  • 規(guī)格：
    ￥83486
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    FCGRT（Rozanolixizumab Biosimilar Antibody)重組單克隆抗體是一種針對新生兒Fc受體（FCGRT）的生物治療研究工具，主要用于免疫學(xué)、藥理學(xué)及相關(guān)疾病機(jī)制的科研探索。該抗體通過特異性結(jié)合FCGRT，可調(diào)節(jié)免疫球蛋白G（IgG）的體內(nèi)半衰期及免疫效應(yīng)，為研究抗體介導(dǎo)的免疫調(diào)節(jié)通路提供重要手段。 在科研應(yīng)用中，F(xiàn)CGRT重組單克隆抗體可用于探究Fc受體相關(guān)的免疫調(diào)節(jié)機(jī)制，包括自身免疫性疾病模型中IgG的清除動力學(xué)、B細(xì)胞功能調(diào)控及抗體依賴性細(xì)胞介導(dǎo)的細(xì)胞毒性（ADCC）等過程。通過靶向FCGRT，研究人員能夠深入分析該受體在維持抗體穩(wěn)態(tài)、炎癥反應(yīng)及免疫耐受中的作用，為開發(fā)新型免疫治療策略提供理論依據(jù)。 該重組抗體采用基因工程技術(shù)制備，具有高特異性和親和力，可通過體外細(xì)胞實(shí)驗(yàn)、動物模型研究等多種科研場景驗(yàn)證其生物學(xué)活性。其研究價(jià)值體現(xiàn)在為抗體藥物開發(fā)、免疫疾病發(fā)病機(jī)制解析及Fc受體靶向療法的篩選提供關(guān)鍵實(shí)驗(yàn)材料，助力科研人員在免疫學(xué)前沿領(lǐng)域取得突破性進(jìn)展。 目前，F(xiàn)CGRT（Rozanolixizumab Biosimilar Antibody)重組單克隆抗體僅作為科研試劑使用，尚未用于臨床治療。研究機(jī)構(gòu)可利用該工具開展Fc受體相關(guān)的基礎(chǔ)研究與轉(zhuǎn)化醫(yī)學(xué)探索，推動對免疫調(diào)節(jié)網(wǎng)絡(luò)的深入理解，為相關(guān)疾病的診斷與治療技術(shù)創(chuàng)新奠定基礎(chǔ)。
  • Uniprot No.：
  • 基因名：
  • 別名：
    A8A research-grade biosimilar; Rozanolixizumab research-grade biosimilar; Rozanolixizumab-noli research-grade biosimilar; Rystiggo research-grade biosimilar; UCB004 research-grade biosimilar; UCB7665 research-grade biosimilar; UCB-7665 research-grade biosimilar; ????? research-grade biosimilar ;FCGRT antibody; FCRN antibody; IgG receptor FcRn large subunit p51 antibody; FcRn antibody; IgG Fc fragment receptor transporter alpha chain antibody; Neonatal Fc receptor antibody
  • 反應(yīng)種屬：
    Human
  • 免疫原：
    Recombinant Human FCGRT protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標(biāo)記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產(chǎn)品提供形式：
    Liquid
  • 應(yīng)用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    3-4 weeks
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產(chǎn)品評價(jià)

靶點(diǎn)詳情

  • 功能：
    Cell surface receptor that transfers passive humoral immunity from the mother to the newborn. Binds to the Fc region of monomeric immunoglobulin gamma and mediates its selective uptake from milk. IgG in the milk is bound at the apical surface of the intestinal epithelium. The resultant FcRn-IgG complexes are transcytosed across the intestinal epithelium and IgG is released from FcRn into blood or tissue fluids. Throughout life, contributes to effective humoral immunity by recycling IgG and extending its half-life in the circulation. Mechanistically, monomeric IgG binding to FcRn in acidic endosomes of endothelial and hematopoietic cells recycles IgG to the cell surface where it is released into the circulation. In addition of IgG, regulates homeostasis of the other most abundant circulating protein albumin/ALB.; (Microbial infection) Acts as an uncoating receptor for a panel of echoviruses including Echovirus 5, 6, 7, 9, 11, 13, 25 and 29.
  • 基因功能參考文獻(xiàn)：
    1. As expected, recombinant factor IX (without albumin fusion) and an FcRn interaction-defective albumin variant localized to the lysosomal compartments of both FcRn-expressing and nonexpressing cells. These results indicate that FcRn-mediated recycling via the albumin moiety is a mechanism for the half-life extension of rIX-FP observed in clinical studies. PMID: 29523681
    2. Regulation of the Human Fc-Neonatal Receptor alpha-Chain Gene FCGRT by MicroRNA-3181. PMID: 29302759
    3. we have demonstrated that loss of FcRn expression promotes tumor cell growth and proliferation. Our data support a model in which FcRn-mediated recycling of albumin reduces amino acid availability to fuel metabolic pathways. PMID: 27974681
    4. An arginine-to-histidine replacement at residue 435 in the binding domain of IgG3 to FcRn increases the transplacental transfer and half-life of malaria-specific IgG3 in young infants and is associated with reduced risk of clinical malaria during infancy. PMID: 28991911
    5. these findings establish a novel mechanism of humoral protection in the eye involving FcRn and may facilitate vaccine and therapeutic development for other ocular surface diseases PMID: 28760885
    6. Data suggest that, unlike albumin with low FcRn-binding affinity, albumin with high FcRn-binding affinity (due to genetic variation/genetic engineering) is directed less to lysosomes and more to endosomes, suggestive of FcRn-directed albumin salvage from lysosomal degradation. (FcRn = neonatal Fc receptor) PMID: 28637874
    7. the localization of FcRn alpha-chain in fixed nasal tissue, was studied. PMID: 26634928
    8. FcRn is involved in transport of aflibercept through REC in vitro. PMID: 27836572
    9. this study shows that FcRn may be associated with the transport and metabolism of IgG in thyrocytes and that transport is independent of IgG type, and that FcRn may be involved in Hashimoto's thyroiditis pathogenesis PMID: 28081504
    10. This review summarizes the main findings on Fc Receptor neonatal biology, function and distribution throughout different tissues. PMID: 27016466
    11. The results suggest that regardless of hyperglycemia degree, it decreases FcRn expression in placenta and blood cells and compromises the production and transfer of antibodies from maternal blood to newborns. PMID: 27469170
    12. Data indicate improved pharmacokinetics through enhanced neonatal Fc receptor (FcRn) interactions were apparent for a complementarity-determining region (CDR) charge-patch normalized monoclonal antibody (mAb) which was affected by non-specific clearance. PMID: 26337808
    13. analysis of binding motifs in the hFCGRT promoter that interact with their corresponding (Sp1, Sp2, Sp3, c-Fos, c-Jun, YY1, and C/EBPbeta or C/EBPdelta) transcription factors (TFs) suggests their involvement in regulation of human FCGRT gene expression PMID: 26252948
    14. These data indicate that human FcRn facilitates the transepithelial transport of IgE in the form of IgG anti-IgE/IgE ICs. PMID: 25652137
    15. Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris. PMID: 26260795
    16. FcRn binding activity of a large set of Fc-fusion samples after thermal stress, was investigated. PMID: 26254986
    17. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity. PMID: 25658443
    18. These results suggest that hFcRn Tgm are a valuable and useful tool for pharmacokinetic screening of mAbs and Fc-fusion proteins in the preclinical stage. PMID: 25030041
    19. The extents of IgG expression in 86 lung cancers were found to associate with clinical stage, pathological grade and lymph node metastasis. PMID: 24853685
    20. Molecular dynamic simulations of human FcRn-Fc binding structures proposed that the protein-protein binding interface is composed of three subsites. PMID: 24057047
    21. This mAb panel provides a powerful resource for probing the biology of human FcRn and for the evaluation of therapeutic FcRn blockade strategies. PMID: 22453095
    22. domain I and III of albumin required for optimal pH-dependent binding to the neonatal Fc receptor PMID: 25344603
    23. Characterization and screening of IgG binding to the neonatal Fc receptor. PMID: 24802048
    24. In intestine, there was an increasing proximal-distal gradient of mucosal FcRn mRNA and protein expression. PMID: 24072267
    25. A cluster of conserved tryptophan residues of FcRn is required for binding to albumin and anti-FcRn albumin blocking antibodies. PMID: 24764301
    26. Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding. PMID: 24652290
    27. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PMID: 24278022
    28. analysis of neonatal Fc receptor-based recycling mechanisms through identification of the human Fc interaction with human FcRn PMID: 24469444
    29. FcRn has the potential to interact with IgG-Fc domains in the ciliary epithelium and retinal and choroidal vasculature, which might affect the half-life and distribution of intravitreally injected Fc-carrying molecules. PMID: 24550358
    30. Only the unbound receptor or FcRn bound to monomeric IgG is sorted into recycling tubules emerging from early endosomes. PMID: 23741050
    31. Analytical FcRn chromatography allows differentiation of IgG samples and variants by peak pattern and retention time profile. PMID: 23765230
    32. The FCGRT promoter VNTR may influence mAbs' distribution in the body. CNV of FCGRT cannot be used as a relevant pharmacogenetic marker because of its low frequency. PMID: 23751752
    33. Studies indicate that high levels of endogenous IgG can compete with the monoclonal antibodies (mAbs) for binding to the neonatal Fc receptor (FcRn). PMID: 23917469
    34. Data indicate that Fc-neonatal Fc receptor (FcRn) interaction is pH dependent. PMID: 23384837
    35. Human FcRn was visualized in epithelial cells of Tg276 mice, but low serum hIgG levels were obtained PMID: 23220220
    36. genetic polymorphism is associated with the efficiency of Ig replacement therapy in common variable immunodeficiency PMID: 23286945
    37. Serum half-life of IgG is controlled by the neonatal Fc receptor (FcRn) that interacts with the IgG Fc region and may be increased or decreased as a function of altered FcRn binding. PMID: 22570488
    38. Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor PMID: 22215085
    39. FcRn transgene blockade is a primary contributing factor toward reduction in arthritis severity; engineering of antibody Fc regions to generate potent FcRn blockers holds promise for the therapy of antibody-mediated autoimmunity in experimental arthritis. PMID: 21690327
    40. Thirty-three genetic variations of FCGRT, including 17 novel ones, were found. PMID: 20930418
    41. These studies demonstrate that FcRn-mediated transport is a mechanism by which IgG can act locally in the female genital tract in immune surveillance and in host defense against sexually transmitted diseases. PMID: 21368166
    42. Methionine (Met) oxidation can result in a significant reduction of the serum circulation half-life and the magnitude of the change correlates well with the extent of Met oxidation and changes in FcRn binding affinities. PMID: 21256596
    43. promoter polymorphism is not associted with the rate of maternal-fetal IgG transfer PMID: 20452034
    44. the x-ray crystal structure of a representative monomeric peptide in complex with human FcRn PMID: 20592032
    45. influence of FcRn expression on disease phenotype and the catabolism of therapeutically administered intravenous immunoglobulins in 28 patients with common variable immunodeficiency PMID: 20627700
    46. No binding of albumin was observed at physiological pH to neonatal Fc receptor. At acidic pH, a 100-fold difference in binding affinity was observed. PMID: 20018855
    47. A recombinant truncated HSA variant, HSA(Bartin), does not interact with FcRn, which gives a molecular explanation for the low serum levels. PMID: 20006594
    48. Affinities to FcRn of clinically used therapeutic proteins are closely correlated with the serum half-lives reported from clinical studies, and suggest an important role of FcRn in regulating the serum half-lives of the therapeutic proteins. PMID: 20083659
    49. Human FcRn binds selectively to human, rabbit and guinea pig IgG but not significantly to rat, bovine, sheep or mouse IgG (except for weak binding to mouse IgG2b). PMID: 11717196
    50. Assembly of the FcRn alpha-chain with beta(2)microglobulin is important for both transport of FcRn from the ER to the cell surface and efficient pH-dependent IgG binding. PMID: 12006623

    顯示更多

    收起更多

  • 亞細(xì)胞定位：
    Cell membrane; Single-pass type I membrane protein. Endosome membrane.
  • 蛋白家族：
    Immunoglobulin superfamily
  • 組織特異性：
    Expressed in full-term placenta, heart, lung, liver, muscle, kidney, pancreas, and both fetal and adult small intestine.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 3621

    OMIM: 601437

    KEGG: hsa:2217

    STRING: 9606.ENSP00000221466

    UniGene: Hs.111903



×
生命科學(xué)計(jì)算平臺